Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring

Overview

Journal Front Oncol

Specialty Oncology

Date 2016 Mar 15

PMID 26973812

Citations 29

Authors

Amarnath Challapalli

Eric O Aboagye

Affiliations

Soon will be listed here.

Abstract

Cancer cells do reprogram their energy metabolism to enable several functions, such as generation of biomass including membrane biosynthesis, and overcoming bioenergetic and redox stress. In this article, we review both established and evolving radioprobes developed in association with positron emission tomography (PET) to detect tumor cell metabolism and effect of treatment. Measurement of enhanced tumor cell glycolysis using 2-deoxy-2-[(18)F]fluoro-D-glucose is well established in the clinic. Analogs of choline, including [(11)C]choline and various fluorinated derivatives are being tested in several cancer types clinically with PET. In addition to these, there is an evolving array of metabolic tracers for measuring intracellular transport of glutamine and other amino acids or for measuring glycogenesis, as well as probes used as surrogates for fatty acid synthesis or precursors for fatty acid oxidation. In addition to providing us with opportunities for examining the complex regulation of reprogramed energy metabolism in living subjects, the PET methods open up opportunities for monitoring pharmacological activity of new therapies that directly or indirectly inhibit tumor cell metabolism.

Citing Articles

Nuclear Medicine Imaging Techniques in Glioblastomas.

Harbi E, Aschner M Neurochem Res. 2024; 49(11):3006-3013.

PMID: 39235579 DOI: 10.1007/s11064-024-04233-6.

ImmunoPET provides a novel way to visualize the CD103 tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

Fan X, Nijman H, de Bruyn M, Elsinga P EJNMMI Res. 2024; 14(1):5.

PMID: 38182929 PMC: 10769965. DOI: 10.1186/s13550-023-01062-6.

Label-free spatially maintained measurements of metabolic phenotypes in cells.

Hu L, Wang N, Bryant J, Liu L, Xie L, Phillip West A Front Bioeng Biotechnol. 2023; 11:1293268.

PMID: 38090715 PMC: 10715269. DOI: 10.3389/fbioe.2023.1293268.

Prospective validation of 18F-Fluoroethylcholine as a tracer in PET/MRI for the evaluation of breast lesions and prediction of lymph node status.

Clauser P, Rasul S, Kapetas P, Fueger B, Milos R, Balber T Radiol Med. 2023; 128(6):689-698.

PMID: 37221356 PMC: 10264497. DOI: 10.1007/s11547-023-01633-6.

Development of Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration.

Kol A, Fan X, Wazynska M, van Duijnhoven S, Giesen D, Plat A J Immunother Cancer. 2023; 10(12).

PMID: 36600560 PMC: 9723959. DOI: 10.1136/jitc-2022-004877.

References

Jager P, Que T, Vaalburg W, Pruim J, Elsinga P, Plukker J . Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. Eur J Nucl Med. 2001; 28(12):1845-9. DOI: 10.1007/s002590100655. View

Amzat R, Taleghani P, Miller D, Beitler J, Bellamy L, Nye J . Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. Mol Imaging Biol. 2013; 15(5):633-43. DOI: 10.1007/s11307-012-0606-7. View

Amanie J, Jans H, Wuest M, Pervez N, Murtha A, Usmani N . Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy. Curr Oncol. 2013; 20(2):104-10. PMC: 3615852. DOI: 10.3747/co.20.1217. View

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W . Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008; 35(10):1766-74. DOI: 10.1007/s00259-008-0788-z. View

Smith G, Zhao Y, Leyton J, Shan B, Nguyen Q, Perumal M . Radiosynthesis and pre-clinical evaluation of [(18)F]fluoro-[1,2-(2)H(4)]choline. Nucl Med Biol. 2011; 38(1):39-51. DOI: 10.1016/j.nucmedbio.2010.06.012. View

Al-Saeedi F . Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study. Curr Ther Res Clin Exp. 2014; 68(4):226-41. PMC: 3967349. DOI: 10.1016/j.curtheres.2007.08.003. View

Luckerath K, Lapa C, Albert C, Herrmann K, Jorg G, Samnick S . 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. Oncotarget. 2015; 6(10):8418-29. PMC: 4480763. DOI: 10.18632/oncotarget.3053. View

Galldiks N, Ullrich R, Schroeter M, Fink G, Kracht L . Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. J Neurooncol. 2009; 93(3):425-30. PMC: 2758365. DOI: 10.1007/s11060-008-9790-3. View

Oyama N, Kim J, Jones L, Mercer N, Engelbach J, Sharp T . MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol. 2002; 29(8):783-90. DOI: 10.1016/s0969-8051(02)00346-3. View

10.

Lin C, Ho C, Ng S, Wang P, Huang Y, Lin Y . (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment. Eur J Nucl Med Mol Imaging. 2013; 41(1):41-9. DOI: 10.1007/s00259-013-2520-x. View

11.

Rajagopalan K, DeBerardinis R . Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med. 2011; 52(7):1005-8. PMC: 3337771. DOI: 10.2967/jnumed.110.084244. View

12.

Hasebe M, Yoshikawa K, Ohashi S, Toubaru S, Kawaguchi K, Sato J . A study on the prognostic evaluation of carbon ion radiotherapy for head and neck adenocarcinoma with C-11 methionine PET. Mol Imaging Biol. 2010; 12(5):554-62. DOI: 10.1007/s11307-010-0318-9. View

13.

Higashi K, Clavo A, Wahl R . In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med. 1993; 34(5):773-9. View

14.

van Waarde A, Elsinga P . Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008; 14(31):3326-339. DOI: 10.2174/138161208786549399. View

15.

Letocha H, Ahlstrom H, Malmstrom P, Westlin J, Fasth K, Nilsson S . Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Urol. 1994; 74(6):767-74. DOI: 10.1111/j.1464-410x.1994.tb07123.x. View

16.

Sato K, Kameyama M, Kayama T, Yoshimoto T, Ishiwata K, Ito M . Serial positron emission tomography imaging of changes in amino acid metabolism in low grade astrocytoma after radio- and chemotherapy-- Case report. Neurol Med Chir (Tokyo). 1995; 35(11):808-12. DOI: 10.2176/nmc.35.808. View

17.

El-Galaly T, Hutchings M . Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. Cancer Treat Res. 2015; 165:125-46. DOI: 10.1007/978-3-319-13150-4_5. View

18.

Schuster D, Votaw J, Nieh P, Yu W, Nye J, Master V . Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48(1):56-63. View

19.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

20.

Liu V, Vander Heiden M . The Role of Pyruvate Kinase M2 in Cancer Metabolism. Brain Pathol. 2015; 25(6):781-3. PMC: 8029046. DOI: 10.1111/bpa.12311. View